Homocysteine and coronary risk.
Hyperhomocysteinemia has recently emerged as a potentially major risk factor in the pathogenesis of coronary artery disease. Various genetic and nongenetic factors influence plasma homocysteine status. The mechanism associating hyperhomocysteinemia with atherosclerosis, if any, is still unclear, but homocysteine may have an adverse effect on vascular endothelium. Folic acid in low doses may ameliorate this process. Several studies are examining the influence of homocysteine-lowering therapy with folic acid on the risk of atherosclerotic vascular disease.
Seshadri
N
N
Desk F15, Department of Cardiology, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
Robinson
K
K
D000367:Age Factors; D002986:Clinical Trials as Topic; D003324:Coronary Artery Disease / Q000209:etiology*; D005260:Female; D005492:Folic Acid / Q000627:therapeutic use*; D006710:Homocysteine / Q000097:blood / Q000378:metabolism; D006801:Humans; D020138:Hyperhomocysteinemia / Q000150:complications* / Q000188:drug therapy* / Q000235:genetics; D008019:Life Style; D008297:Male; D012307:Risk Factors; D012737:Sex Factors
D006710:Homocysteine; D005492:Folic Acid